Bortezomib May Improve Outcomes in Multiple Myeloma
Adding bortezomib to combination therapy with lenalidomide and dexamethasone may improve progression-free and overall survival in patients with newly diagnosed multiple myeloma. The study findings were published in Lancet.
Combination Therapy Shows Promise for Chronic Myeloid Leukemia
According to the results of a new study published in Science Translational Medicine, a combination regimen consisting of a BCR-ABL tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor may one day result in a cure for chronic myeloid leukemia.